Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats

다국어 초록 (Multilingual Abstract)

Objectives: The effects of Gamiondam-tang (GMODT) co-administration within 5min on the pharmacokinetics (PK) of tamoxifen were observed as a process of the comprehensive and integrative medicine, combination therapy of tamoxifen with GMODT to achieve synergic pharmacodynamics and reduce toxicity on the breast cancer.
Methods: After 50mg/kg of tamoxifen treatment, GMODT 100mg/kg was administered within 5min. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of GMODT treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. PK parameters of tamoxifen (Tmax, Cmax, AUC, t1/2 and MRTinf) were analysis as compared with tamoxifen single administered rats using noncompartmental pharmacokinetics data analyzer programs.
Results: Co-administration with GMODT induced increased trends of plasma tamoxifen concentrations to 1hr after end of administration, and then showed decreased trends of plasma tamoxifen concentrations, and especially significant (p<0.05) increases of plasma tamoxifen concentrations were demonstrated at 0.5hr after end of co-administration with GMODT and also related significant (p<0.05) decreases of AUC0-inf and MRTinf as compared with tamoxifen single formula treated rats, at dosage levels of tamoxifen 10 mg/kg and GMODT 100 mg/kg within 5 min, in this experiment.
Conclusion: Based on the results of the present study, it is considered that single co-administration GMODT within 5min significantly inhibited the oral bioavailability of tamoxifen through variable influences on the absorption and excretion of tamoxifen, can be influenced on the toxicity or pharmacodynamic of tamoxifen.

참고문헌 (Reference)

1 Kim SY, "a-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes" 16 (16): 1138-1144, 2003

2 "Zeneca Pharmaceuticals. Nolvadex (tamoxifen citrate) prescribing information"

3 Braems G, "Use of tamoxifen before and during pregnancy" 16 (16): 1547-1551, 2011

4 Nalbandian G, "The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation" 175 (175): 2666-2675, 2005

5 Dehal SS, "The aromatase inactivator 4-hydroxyandrostenedione(4-OH-A)inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A : potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy" 27 (27): 389-394, 1999

6 Bailer AJ, "Testing for the equality of area under the curves when using destructive measurement techniques" 16 (16): 303-309, 1988

7 Ritchie LD, "Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file" 298 (298): 1253-, 1989

8 Osman KA, "Tamoxifen-induced non-alcoholic steatohepatitis:where are we now and where are we going?" 6 (6): 1-4, 2007

9 Grilli S, "Tamoxifen(TAM) : the dispute goes on" 42 (42): 170-173, 2006

10 Eugster EA, "Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome" 12 (12): 681-686, 1999

11 Vehmanen L, "Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status" 24 (24): 675-680, 2006

12 Reid AD, "Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients" 22 (22): 153-156, 1992

13 Blackwell KL, "Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models" 6 (6): 4359-4364, 2000

14 Sawathiparnich P, "Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome : patient report and literature review" 19 (19): 81-86, 2006

15 Karimian E, "Tamoxifen impairs both longitudinal and cortical bone growth in young male rats" 23 (23): 1267-1277, 2008

16 Fisher B, "Tamoxifen for prevention of breast cancer : report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study" 90 (90): 1371-1388, 1998

17 Karn A, "Tamoxifen for breast cancer" 49 (49): 62-67, 2010

18 Rousset-Jablonski C, "Tamoxifen contraindicated in women with hereditary angioedema?" 20 (20): 1281-1282, 2009

19 Fradet Y, "Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer : a randomised, placebo-controlled, dose-response study" 52 (52): 106-114, 2007

20 Jordan VC, "Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer" 147 (147): S269-S276, 2006

21 Adam HK, "Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers" 64 (64): 761-764, 1980

22 Dabelic N, "Riedel's thyroiditis treated with tamoxifen" 44 (44): 239-241, 2003

23 Cella D, "Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy" 107 (107): 167-180, 2008

24 Cella D, "Quality of life of postmenopausal women in the ATAC("Arimidex", tamoxifen, alone or in combination)trial after completion of 5 years' adjuvant treatment for early breast cancer" 100 (100): 273-284, 2006

25 Einat H, "Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder" 55 (55): 123-131, 2007

26 Nakagawasai O, "Preventive effect of kami-untan-to on performance in the forced swimming test in thiamine-deficient mice : relationship to functions of catecholaminergic neurons" 177 (177): 315-321, 2007

27 Paganini-Hill A, "Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen" 64 (64): 165-176, 2000

28 Wang Q, "Potentiation of brain acetylcholine neurons by Kami-Untan-To(KUT)in aged mice : implications for a possible antidementia drug" 7 (7): 253-258, 2000

29 Lerner HJ, "Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer" 60 (60): 1431-1435, 1976

30 Gibaldi M, "Pharmacokinetics" Taylor & Francis 1982

31 Hall WA, "Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas" 77 (77): 279-284, 2006

32 Jordan VC, "Metabolites of tamoxifen in animals and man : identification, pharmacology, and significance" 2 (2): 123-138, 1982

33 Mani C, "Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation" 21 (21): 645-656, 1993

34 Adam HK, "Measurement of tamoxifen in serum by thin-layer densitometry" 84 (84): 35-42, 1980

35 Berstein LM, "Long-term exposure to tamoxifen induces hypersensitivity to estradiol" 10 (10): 1530-1534, 2004

36 Feil R, "Ligand-activated site-specific recombination in mice" 93 (93): 10887-10890, 1996

37 Tenni P, "Life threatening interaction between tamoxifen and warfarin" 298 (298): 93-, 1989

38 The BIG 1-98 Collaborative Group, "Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer" 361 (361): 766-776, 2009

39 Oh HK, "Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice" 146 (146): 600-607, 2013

40 Mani C, "Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes" 15 (15): 2715-2720, 1994

41 Fatourechi MM, "Invasive fibrous thyroiditis(Riedel thyroiditis) : the Mayo Clinic experience, 1976-2008" 21 (21): 765-772, 2011

42 Dowsett M, "Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer" 5 (5): 2338-2343, 1999

43 Sun D, "Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases" 35 (35): 2006-2014, 2007

44 Jordan VC, "Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer" 110 (110): 507-517, 1993

45 Wilson SC, "Evidence for the involvement of central conversion of testosterone to oestradiol-17b in the regulation of luteinizing hormone secretion in the cockerel" 99 (99): 301-310, 1983

46 Boccardo F, "Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer" 23 (23): 808-815, 2005

47 Eberling JL, "Estrogen-and tamoxifen-associated effects on brain structure and function" 21 (21): 364-371, 2004

48 Decensi A, "Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial" 111 (111): 650-656, 2005

49 Mortimer JE, "Effect of tamoxifen on sexual functioning in patients with breast cancer" 17 (17): 1488-1492, 1999

50 Nakagawasai O, "Effect of kami-untan-to on the impairment of learning and memory induced by thiamine-deficient feeding in mice" 125 (125): 233-241, 2004

51 박수진, "Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration" 대한예방한의학회 20 (20): 97-109, 2016

52 곽민아, "Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) - Single Oral Combination Treatment of Tamoxifen 50mg/kg with JEKHT 100 mg/kg within 5 min -" 대한한의학회 37 (37): 1-11, 2016

53 Amrollahi Z, "Double -blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania" 129 (129): 327-331, 2011

54 Lamberts SW, "Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells" 63 (63): 1342-1347, 1986

55 Jordan VC, "Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer" 43 (43): 1446-1450, 1983

56 Redmond CK, "Design and current status of the NSABP breast cancer prevention trial. Recent results in cancer research. Fortschritte der Krebsforschung" 140 : 309-317, 1996

57 Lien EA, "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide" 50 (50): 5851-5857, 1990

58 Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve" 6 (6): 539-546, 1978

59 Kelly HL, "Concomitant pregnancy and breast cancer : options for systemic therapy" 23 : 95-101, 2005

60 Steiner AZ, "Comparison of tamoxifen and clomiphene citrate for ovulation induction : a meta-analysis" 20 (20): 1511-1515, 2005

61 Williams JA, "Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7" 30 (30): 883-891, 2002

62 Fabian C, "Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules" 64 (64): 765-773, 1980

63 Notley LM, "Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a, 4-dihydroxy derivatives" 18 (18): 1611-1618, 2005

64 van Bommel EF, "Brief communication : tamoxifen therapy for nonmalignant retroperitoneal fibrosis" 144 (144): 101-106, 2006

65 "AstraZeneca Pharmaceuticals" Nolvadex (tamoxifen citrate) prescribing information 2003

66 Murphy C, "Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry(GC-MS)using selected ion monitoring(SIM)" 26 (26): 547-555, 1987

67 West CM, "Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells" 55 (55): 159-163, 1990

68 Pienta KJ, "A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate" 19 (19): 500-503, 1996